AU2013302497A1 - Novel kappa opioid ligands - Google Patents

Novel kappa opioid ligands Download PDF

Info

Publication number
AU2013302497A1
AU2013302497A1 AU2013302497A AU2013302497A AU2013302497A1 AU 2013302497 A1 AU2013302497 A1 AU 2013302497A1 AU 2013302497 A AU2013302497 A AU 2013302497A AU 2013302497 A AU2013302497 A AU 2013302497A AU 2013302497 A1 AU2013302497 A1 AU 2013302497A1
Authority
AU
Australia
Prior art keywords
rac
omeh
trans
pct
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013302497A
Other languages
English (en)
Inventor
Miguel A. Guerrero
Edward Roberts
Hugh Rosen
Mariangela URBANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2013302497A1 publication Critical patent/AU2013302497A1/en
Priority to AU2018201522A priority Critical patent/AU2018201522A1/en
Priority to AU2019246921A priority patent/AU2019246921B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
AU2013302497A 2012-08-16 2013-08-16 Novel kappa opioid ligands Abandoned AU2013302497A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018201522A AU2018201522A1 (en) 2012-08-16 2018-03-02 Novel kappa opioid ligands
AU2019246921A AU2019246921B2 (en) 2012-08-16 2019-10-11 Novel kappa opioid ligands

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683861P 2012-08-16 2012-08-16
US61/683,861 2012-08-16
PCT/US2013/055313 WO2014028829A1 (en) 2012-08-16 2013-08-16 Novel kappa opioid ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201522A Division AU2018201522A1 (en) 2012-08-16 2018-03-02 Novel kappa opioid ligands

Publications (1)

Publication Number Publication Date
AU2013302497A1 true AU2013302497A1 (en) 2015-03-05

Family

ID=50101521

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013302497A Abandoned AU2013302497A1 (en) 2012-08-16 2013-08-16 Novel kappa opioid ligands
AU2018201522A Abandoned AU2018201522A1 (en) 2012-08-16 2018-03-02 Novel kappa opioid ligands
AU2019246921A Active AU2019246921B2 (en) 2012-08-16 2019-10-11 Novel kappa opioid ligands

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018201522A Abandoned AU2018201522A1 (en) 2012-08-16 2018-03-02 Novel kappa opioid ligands
AU2019246921A Active AU2019246921B2 (en) 2012-08-16 2019-10-11 Novel kappa opioid ligands

Country Status (8)

Country Link
US (4) US9682966B2 (https=)
EP (2) EP2884978B1 (https=)
JP (3) JP6254163B2 (https=)
AU (3) AU2013302497A1 (https=)
CA (1) CA2882132C (https=)
DK (1) DK2884978T3 (https=)
ES (1) ES2750640T3 (https=)
WO (1) WO2014028829A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2884978B1 (en) 2012-08-16 2019-07-17 The Scripps Research Institute Novel kappa opioid ligands
US10982041B2 (en) * 2016-02-25 2021-04-20 Swancor Advanced Materials Co., Ltd. Epoxy resin oligomer
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
AU2018234931B2 (en) * 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP3723751A4 (en) * 2017-12-08 2021-07-07 The Rockefeller University KAPPA PYRANO [3,4-B] PYRAZINE OPIOID RECEIVER LIGANDS FOR THE TREATMENT OF ADDICTION, PRURITUS, PAIN AND INFLAMMATION
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
IL322808A (en) * 2023-02-17 2025-10-01 Scripps Research Inst Quinoline derivatives used as kappa-opioid receptor agonists
WO2024216046A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
CN121866250A (zh) * 2023-08-18 2026-04-14 斯克里普斯研究学院 κ-阿片受体拮抗剂
WO2025051204A1 (zh) * 2023-09-05 2025-03-13 海思科医药集团股份有限公司 一种kor拮抗剂及其在医药上的应用
WO2025250535A1 (en) 2024-05-28 2025-12-04 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
WO2025257758A1 (en) 2024-06-11 2025-12-18 Assia Chemical Industries Ltd. Solid state forms of navacaprant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014171A1 (de) * 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
KR970011390B1 (ko) 1992-01-23 1997-07-10 도레이 가부시키가이샤 모르피난 유도체와 약리학적으로 허용되는 이의 산 부가염 및 이를 함유하는 약제학적 조성물
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
WO1999054305A1 (de) * 1998-04-20 1999-10-28 Basf Aktiengesellschaft Heterocyclisch substituierte amide als calpainhemmer
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
ATE533745T1 (de) * 2004-03-17 2011-12-15 Pfizer Prod Inc Neue benzyl(iden)-lactam-derivate
ATE482213T1 (de) * 2004-11-04 2010-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GB0510204D0 (en) * 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
PE20110285A1 (es) 2005-10-19 2011-06-04 Gruenenthal Chemie Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
AU2006306542B2 (en) * 2005-10-21 2012-04-19 Merck Sharp & Dohme Corp. Potassium channel inhibitors
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
CN102015684A (zh) * 2007-12-10 2011-04-13 葛兰素集团有限公司 联-吡啶基吡啶酮作为黑色素浓缩激素受体1拮抗剂
WO2011025799A1 (en) * 2009-08-26 2011-03-03 Glaxo Group Limited Cathepsin c inhibitors
ES2585806T3 (es) * 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
BR112012016201A2 (pt) * 2009-12-29 2017-12-19 Suven Life Sciences Ltd ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8486968B2 (en) * 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8822471B2 (en) 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2884978B1 (en) 2012-08-16 2019-07-17 The Scripps Research Institute Novel kappa opioid ligands

Also Published As

Publication number Publication date
US9682966B2 (en) 2017-06-20
EP3584246A1 (en) 2019-12-25
JP2020090518A (ja) 2020-06-11
ES2750640T3 (es) 2020-03-26
EP2884978A1 (en) 2015-06-24
AU2018201522A1 (en) 2018-03-22
JP2015531764A (ja) 2015-11-05
US10118915B2 (en) 2018-11-06
US20180099954A1 (en) 2018-04-12
AU2019246921A1 (en) 2019-10-31
JP6254163B2 (ja) 2017-12-27
EP2884978A4 (en) 2016-01-13
CA2882132A1 (en) 2014-02-20
AU2019246921B2 (en) 2021-04-01
EP2884978B1 (en) 2019-07-17
US20250346584A1 (en) 2025-11-13
US20150210673A1 (en) 2015-07-30
CA2882132C (en) 2021-07-06
DK2884978T3 (da) 2019-09-30
JP2018058873A (ja) 2018-04-12
US20250066336A1 (en) 2025-02-27
WO2014028829A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AU2019246921B2 (en) Novel kappa opioid ligands
US9586928B2 (en) Modulators of the nuclear hormone receptor ROR
ES2672732T3 (es) Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
US20170327512A1 (en) Modulators of vasopressin receptors with therapeutic potential
WO2012009258A2 (en) Peptidomimetic galanin receptor modulators
US9051265B2 (en) N-benzylindole modulators of PPARG
WO2017152126A1 (en) Small molecule ire1-alpha inhibitors
US9656994B2 (en) Substituted benzimidazoles as nociceptin receptor modulators
TW201211029A (en) Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
CN114181207B (zh) β-咔波啉类化合物及其制备方法和抗阿尔兹海默病的应用
US20150246908A1 (en) Klf5 modulators
WO2014116684A1 (en) Non-peptidic neuropeptide y receptor modulators
CN119970736B (zh) 组蛋白去乙酰化酶4小分子抑制剂的合成方法和抗血管内皮衰老的应用
ES2671398T3 (es) Derivados de ciclopentilamina 3-sustituida
EP4255425A1 (en) Imidazole compounds as inhibitors of enpp1

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted